Moderna Inc.

Cambridge, Massachusetts
Pharmaceuticals Biotechnology and Life Sciences

Corporate Bias Rating

Expand Summary

Risk Level:

Rating - Danger
High Risk

Summary:

Moderna scored a 100 on the 2023 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. By complying with Human Rights Campaign’s controversial demands, Moderna increases the risk of dividing employees, alienating customers and harming shareholders. The company covers transgender-related medical costs for its employees and their children and provides specific sexual orientation and gender identity-based benefits. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, marketing, and philanthropic support. Moderna forces employees to undergo multiple ideological trainings and uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. Moderna's CEO signed the CEO Action for Diversity and Inclusion pledge and supports ESG within its business practices. For these reasons, Moderna Inc. receives a High Risk rating.

View Full Report

Board Bias

Expand Summary

CEO of Moderna Inc.

Stephane Bancel

Stephane Bancel

Summary:

Headquartered in Cambridge, Massachusetts, Moderna Inc. is a member of the Fortune 250 operating in the Pharmaceuticals Biotechnology and Life Sciences industry. Stephane Bancel and Noubar Afeyan, Ph.D. serve as CEO/President and Chairman, respectively, leading the company’s C-suite executive team and the board of directors. Amongst these teams, the collective leadership is responsible for $0 to Republican causes and $0 to Democratic causes. Under their tenure, Moderna Inc. currently holds a 'High Risk' risk rating.

View Full Board Bias Report

Political Contributions of Leadership:

$0

$0

Republican

Democrat

Generate Reports
Clear
Toast